Comparing the current results to its competitors, Organogenesis Holdings Inc reported Revenue decrease in the 1 quarter 2026 year on year by -57.06 %, faster than the overall decrease of Organogenesis Holdings Inc 's competitors by -11.18 %, recorded in the same quarter.
Organogenesis Holdings Inc 's Comment on Competition and Industry Peers
The company utilizes intellectual property, know-how, and technological innovation to sustain its competitive position. It holds licenses from Novartis Pharma AG for Apligraf and from RESORBA Medical GmbH for a collagen-based wound dressing patent. As of December 31, 2025, the company owns 53 issued patents worldwide and has 17 pending patent applications. Its competitive advantages include product efficacy, a broad portfolio, customer support, reimbursement success, relationships with group purchasing organizations, and established clinical evidence. The company is among the few regenerative medicine firms offering PMA-approved and 510(k) cleared products alongside 361 HCT/Ps.
Risks to operating results include the introduction of new competitor products, reimbursement failures, changes in Medicare payment policies favoring competitors, and modifications to healthcare program policies. The company operates in a rapidly changing technological environment with intense competition and acknowledges that others may develop superior products or processes. Its success depends on identifying customer needs, timely product development, intellectual property protection, clinical trial outcomes, and regulatory approvals. Physician adoption of its products relies on demonstrated safety, efficacy, and favorable clinical data compared to conventional treatments. Competitors identified include Novartis Pharma AG and RESORBA Medical GmbH.
Biostage Inc is a company that aims to develop and commercialize bioengineered organ implants for the treatment of life-threatening conditions. They utilize their proprietary CellFrame technology to create personalized, implantable organs that can potentially restore and regenerate damaged tissue.
Sanara Medtech Inc's business model focuses on developing and providing innovative medical technologies and solutions for wound care, aiming to improve patient outcomes and address unmet needs in the healthcare industry.
Regen Biopharma Inc is a biotechnology company that focuses on developing innovative treatments for diseases like cancer and autoimmune disorders. Their business model revolves around conducting research and development activities to create novel therapeutics and licensing or partnering with larger pharmaceutical companies for further development and commercialization. By leveraging their scientific expertise and strategic collaborations, Regen Biopharma aims to bring cutting-edge medical solutions to the market and improve patient outcomes.
Avita Medical Inc is a medical technology company that specializes in regenerative medicine. Their business model focuses on developing and commercializing innovative products for the treatment of burns, chronic wounds, and other skin-related conditions.
Nuo Therapeutics Inc's business model revolves around developing and commercializing innovative biologic therapies aimed at improving healthcare outcomes for patients. They focus on the research, development, and marketing of new therapeutic products, primarily in the wound care sector.
Sources:
Organogenesis Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Organogenesis Holdings Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
